Production (Stage)
E
AnaptysBio, Inc. ANAB
$20.44 -$0.30-1.45% NASDAQ
Recommendation
Prev Close
$20.44
Volume
357,651
Avg Vol (90D)
886,144
Market Cap
$600.54M
Dividend & Yield
--
52-Week Range
$12.21 - $41.31
P/E (TTM)
--
EPS (TTM)
-$4.84
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Woodline Partners LP Raises Stake in AnaptysBio, Inc. (NASDAQ:ANAB)
5/24/2025 - Ticker Report
Frazier Life Sciences Management L.P. Reduces Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)
5/23/2025 - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Rafferty Asset Management LLC
5/22/2025 - Ticker Report
D. E. Shaw & Co. Inc. Sells 27,030 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)
5/22/2025 - MarketBeat
AnaptysBio (ANAB, $21.1) entered Uptrend as Momentum indicator ascends above 0 level on May 20, 2025
5/21/2025 - Tickeron - Stocks
Soleus Capital Management L.P. Invests $5.48 Million in AnaptysBio, Inc. (NASDAQ:ANAB)
5/21/2025 - MarketBeat
Graham Capital Management L.P. Purchases Shares of 18,954 AnaptysBio, Inc. (NASDAQ:ANAB)
5/21/2025 - MarketBeat
Sanofi Purchases New Stake in AnaptysBio, Inc. (NASDAQ:ANAB)
5/19/2025 - MarketBeat
Dimensional Fund Advisors LP Decreases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)
5/19/2025 - MarketBeat
Granahan Investment Management LLC Invests $1.40 Million in AnaptysBio, Inc. (NASDAQ:ANAB)
5/13/2025 - MarketBeat
AnaptysBio (ANAB, $20.03) Stochastic Oscillator left the oversold zone on May 12, 2025
5/13/2025 - Tickeron - Stocks
11 Unstoppable Growth Stocks to Invest in Now
5/12/2025 - Insider Monkey
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of "Moderate Buy" from Analysts
5/12/2025 - MarketBeat
Bridgefront Capital LLC Makes New $252,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB)
5/11/2025 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $54.00 at Guggenheim
5/8/2025 - MarketBeat
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
5/8/2025 - Simply Wall St
AnaptysBio (ANAB, $19.68) Stochastic Oscillator left the oversold zone on May 07, 2025
5/8/2025 - Tickeron - Stocks
AnaptysBio (NASDAQ:ANAB) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
5/7/2025 - MarketBeat
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Iradimed (IRMD) and Sangamo Biosciences (SGMO)
5/7/2025 - TipRanks Financial Blog
Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?
5/7/2025 - Simply Wall St
AnaptysBio First Quarter 2025 Earnings: Beats Expectations
5/7/2025 - Simply Wall St
AnaptysBio (ANAB, $20.12) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 6, 2025
5/7/2025 - Tickeron - Technical Analysis
AnaptysBio (ANAB, $20.12) entered Downtrend as Momentum indicator drops below 0 level on May 06, 2025
5/7/2025 - Tickeron - Technical Analysis
Barclays PLC Boosts Stake in AnaptysBio, Inc. (NASDAQ:ANAB)
5/7/2025 - MarketBeat
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Relay Therapeutics (RLAY) and Inspire Medical Systems (INSP)
5/7/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$111.87M
EBITDA (TTM)
-$99.70M
EBIT (TTM)
-$100.29M
Net Income (TTM)
-$140.62M
Balance Sheet
Total Assets (Q)
$422.05M
Total Debt (Q)
$345.96M
Total Liabilities (Q)
$388.03M
Book Value Per Share (Q)
$1.12
Cash Flow
Cash from Operations (TTM)
-$108.78M
Cash from Investing (TTM)
$41.63M
Cash from Financing (TTM)
$112.10M
Net Change in Cash (TTM)
$44.94M
Filings
Filing Date
Monday, May 5, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.08
7-Day Total Return
0.20%
30-Day Total Return
19.04%
60-Day Total Return
21.52%
90-Day Total Return
32.13%
Year to Date Total Return
52.99%
1-Year Total Return
-14.51%
2-Year Total Return
7.98%
3-Year Total Return
2.30%
5-Year Total Return
4.71%
52-week Low
Feb 11, 2025 - $12.21
52-week High
Aug 14, 2024 - $41.31
Valuation
Market Cap
$600.54M - Small Cap
Enterprise Value
$606.56M
Price/Sales (TTM)
5.60
Price/Book (Q)
18.26
Dividends and Shares
Shares Outstanding
30.64M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.anaptysbio.com
Phone Number
858 362 6295
Address
10770 Wateridge Circle
San Diego, CA 92121-5801
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed